Search results
Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C Virus Infection
… the study for approximately 1 year post transplant. Trial Website: https://clinicaltrials.gov/show/NCT01603108 …
Last Modified:
Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients
… recipients of stem cell or solid organ transplants. Trial Website: https://clinicaltrials.gov/show/NCT01611974 …
Last Modified:
Simtuzumab (GS-6624) in Treatment of Advanced Liver Fibrosis But Not Cirrhosis Secondary to NASH
… Double-Blind Phase Open Label Phase (optional) Trial Website: https://clinicaltrials.gov/show/NCT01672866 …
Last Modified:
A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis
… tablets or placebo tablets every day for 24 weeks. Trial Website: https://clinicaltrials.gov/show/NCT01904409 …
Last Modified:
A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C
… throughout the study as well as efficacy data. Trial Website: https://clinicaltrials.gov/show/NCT02161939 …
Last Modified: